New management of the pregnant patient to reduce the risk of transmitting herpes to the newborn.

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：:Osteoarthritis is the single most important cause of disability and limitation of activity of elderly people in the UK. Although joint replacement is now commonplace for hips and increasingly so for knees, pharmacological management continues to be important. In this context, it is necessary to identify valid and acce...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Walters SJ,Lloyd-Jones M

更新日期：2002-08-01 00:00:00

abstract：:Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rothberg M

更新日期：2005-04-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

更新日期：2020-08-01 00:00:00

abstract：:This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

更新日期：2007-02-01 00:00:00

abstract：:The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2014-04-01 00:00:00

abstract：:Treatment switching has become an important issue in the development and approval of new drugs, particularly in oncology. Randomized controlled trials (RCTs) represent the gold standard for evaluating the effectiveness of interventions, but often patients randomized to the control group are permitted to switch onto th...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Latimer NR

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Chronic pancreatitis (CP) is a leading cause of hospitalization among gastrointestinal diseases resulting in considerable financial burden to patients. However the direct costs for nonsurgical management in CP remains unexplored. METHODS:A cross sectional study was carried out (2011-14) in the Department of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kamat N,Pai G,Mallayasamy SR,Kamath A,S R

更新日期：2018-06-01 00:00:00

abstract：AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Regnier SA,Alsop J,Wright J,Nixon R,Staines H,Fajnkuchen F

更新日期：2016-12-01 00:00:00

abstract：:Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

更新日期：2011-04-01 00:00:00

abstract：OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

更新日期：2018-06-01 00:00:00

abstract：:Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brédart A,Sultan S,Regnault A

更新日期：2010-04-01 00:00:00

abstract：:This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Akincigil A,Wei W,Crystal S

更新日期：2005-06-01 00:00:00

abstract：:The prevalence of multiple chronic conditions (MCC) is increasing among individuals of all ages. MCC are associated with poor health outcomes. The presence of MCC has profound healthcare utilization and cost implications for public and private insurance payers, individuals, and families. Investigators have used a vari...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Tan X,Deb A

更新日期：2015-01-01 00:00:00

abstract：:Osteoporosis is a public health threat to approximately 44 million individuals in the USA, or 55% of men and women over the age of 50 years. The primary goal of osteoporosis management is to prevent fracture, the most devastating consequence. Risk factors and bone mineral density can be assessed to determine appropria...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hansen LB

更新日期：2006-10-01 00:00:00

abstract：:This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effectiv...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Elbeik T,Chen YM,Soutchkov SV,Loftus RA,Beringer S

更新日期：2003-08-01 00:00:00

abstract：:Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Menon D,Stafinski T

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grewal S,Ramsey S,Balu S,Carlson JJ

更新日期：2018-08-01 00:00:00

abstract：:In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grant WC,Yoder DM,Mullins CD

更新日期：2004-04-01 00:00:00

abstract：:Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Doctor JN,Miyamoto JM

更新日期：2005-12-01 00:00:00

abstract：:The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Coretti S,Ruggeri M,McNamee P

更新日期：2014-04-01 00:00:00

abstract：INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wijnen B,Van Mastrigt G,Redekop WK,Majoie H,De Kinderen R,Evers S

更新日期：2016-12-01 00:00:00

abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sankaranarayanan J,Reardon T,Olsen KM

更新日期：2014-10-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：:Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reddy P

更新日期：2002-12-01 00:00:00

abstract：:A review was undertaken to identify relevant and appropriate heath-utility estimates for patients with atrial fibrillation who had stroke and to appraise them against the published requirements for several countries' Health Technology Assessment agencies: Australia (Pharmaceutical Benefits Advisory Committee), Canada ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lloyd A,Wild D,Gallop K,Cowell W

更新日期：2009-12-01 00:00:00

abstract：AIMS:To quantify the relationship between the timing of gastroesophageal reflux disease (GERD) symptoms and the burden of illness. PATIENTS & METHODS:Data from the 2010 National Health and Wellness Survey were used. Regression analyses compared non-GERD controls with GERD patients with diurnal symptoms, nocturnal symp...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wagner JS,DiBonaventura MD,Balu S,Buchner D

更新日期：2011-12-01 00:00:00

abstract：:The aim of this systematic review was to collect all current data on indirect costs related to inflammatory bowel disease as well as assessing homogeneity and comparability, and conducting a meta-analysis. Costs were collected using databases from Medline, Embase and Centre for Reviews and Dissemination databases, the...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kawalec P,Malinowski KP

更新日期：2015-04-01 00:00:00

abstract：:The Dutch basic health insurance is based on the principles of regulated competition. This implies that insurers and providers compete on price and quality while the regulator sets certain rules to achieve public objectives such as solidarity. Two regulatory aspects of this scheme are that insurers are not allowed to ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： van Kleef RC,van de Ven WP,van Vliet RC

更新日期：2013-12-01 00:00:00

abstract：:In response to concerns about the cost burden of medical care in general and rising pharmaceutical costs in particular, a number of recent studies have examined trends in pharmaceutical expenditures. These studies have reached apparently disparate conclusions about factors responsible for rising pharmaceutical costs a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Crown WH,Ling D,Berndt E

更新日期：2002-10-01 00:00:00